Ambu (CPH:AMBU B) Full Year 2022 Results
Key Financial Results
- Revenue: kr.4.44b (up 11% from FY 2021).
- Net income: kr.93.0m (down 62% from FY 2021).
- Profit margin: 2.1% (down from 6.2% in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ambu Meets Expectations
Revenue was in line with analyst estimates.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in Denmark.
The company's shares are down 18% from a week ago.
It is worth noting though that we have found 3 warning signs for Ambu that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether Ambu is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.